** Brokerage Raymond James resumes coverage on drugmaker BridgeBio Pharma BBIO.O with "outperform" rating; sets PT at $57, a 66.4% upside to the stock's last close
** Brokerage anticipates BBIO's launch of heart disease drug Attruby to be faster than expected, even with a significant discount on revenues after 2028 due to potential pricing pressure from the loss of exclusivity for Pfizer's PFE.N tafamidis
** "We expect it to gain meaningful market share in the newly diagnosed population," brokerage adds
** BBIO can leverage its drugs Encaleret and BBP-418 to form partnerships and improve finances — brokerage
** 14 out of 16 brokerages rate the stock "buy" or higher, 2 rate it "hold", per data compiled by LSEG
** Stock has fallen 4.1% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。